bl-m24d1
mAbexperimentalADC
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 11, 2025 (NCT07232420)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
- Payload
- unclear
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07255898 | Phase 1 | Dec 31, 2025 | Baili Pharmaceutical Group |
| NCT07279428 | Phase 1 | Dec 31, 2025 | Baili Pharmaceutical Group |
| NCT07232524 | Phase 1 | Nov 30, 2025 | Baili Pharmaceutical Group |
| NCT07232420 | Phase 1 | Nov 11, 2025 | Baili Pharmaceutical Group |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Baili Pharmaceutical Group | For profit | 4 | 4 | 1 | 2025 |
1 organizations
Page 1 / 1